Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 10/18/21 (What's New)

Switching From a Boosted PI to an INSTI-Based Regimen

Several trials have been undertaken to address the safety and efficacy of modifying boosted PI–based regimens to 3-drug regimens containing dolutegravir, bictegravir, raltegravir, and to ...

Action required